REVIEW ARTICLE

HLA PROFILE AND CLINICAL PRESENTATION OF MULTIPLE SCLEROSIS IN IRAN

H. Kalanie MD [1],
G.R. Shamsai MD [2]

1. Professor of Neurology,
Shahid Beheshti University of
Medical Sciences
2. Assistant Professor of
Neurology, Jundishapoor
University of Medical Sciences
Correspoding Author:
Hossein Kalanie MD
Tel:+98 21 88960081-89
Fax:+98 21 88969155

Abstract:
Multiple sclerosis (MS) is a demyelinating disease of the central nervous system, with unknown etiology in which both genetic and environmental factors are thought to be involved. The HLA system provides a set of genetic markers which lend themselves to systematic study. The disease also has variable clinical manifestations, ranging from a relapsing-remitting course to a chronic progressive disease.
In this article we review HLA profile and clinical presentation of the disease from current available data in Iran.

Key words: HLA, Clinical presentation, MS, Iran

Introduction

Multiple sclerosis (MS) can be regarded as an organ-specific inflammatory disease probably resulting from an aberrant immune response to myelin antigens (1-4). It is a disease of unknown etiology in which both genetic and environmental factors are thought to be involved (5). The HLA system provides a set of genetic markers which lend themselves to systematic study. Evidence continues to accumulate that MS populations differ from local controls in their HLA allele composition (6).

This association varies in different parts of the world probably due to varying racial susceptibility to MS(7-8). Genetic analyses have suggested that the major histocompatibility complex (MHC)/HLA region on chromosome 6p21 contains an MS-predisposing component (9). Which of the many genes present in this region is responsible for MS susceptibility is still an unsettled issue. However results from genomic screens suggest that a number of genes of varying and interacting effects will be implicated and these searches reinforce the genetic epidemiology of the disease (10).

The condition is diagnosed clinically from the demonstration of white matter (WM) dysfunction separated in time and space (11). It is a cause of chronic neurological disability in young and middle-aged adults with and unequal distribution worldwide (2, 12). The variation in prevalence and clinical pattern according to geographical location, probably related to ethnic and environmental factors, has been observed in several studies (13-14). The prevalence is thought to be low in Iran (15) an in other middle-eastern countries (16-20). At present, the current impression in Iran is that more cases are being diagnosed.

The aim of this communication is to highlight the HLA types and clinical course of the disease and its pattern of presentation in the largest sample of cases managed so far in Iran (15, 21).

Factors Contributing to disease susceptibility

A- Environmental factors: Classic studies indicate that MS exhibits distinct geographic clustering within the temperate zones in northern and southern hemisphere (22). Migration studies have been informative regarding the interaction of genetic susceptibility and environment. An individual who moves from a high-risk to a low-risk area during childhood will acquire a low-risk of developing MS (23). By contrast individual moving after adolescence retain the risk of the original location.

B- Genes and susceptibility to MS: the balance of evidence relating to the etiology of multiple sclerosis favours an interplay between genetic susceptibility and environmental trigger. Just as the twin studies show clearly that almost 60% of monozygotic pairs are not concordant for multiple sclerosis (24-26) so is the low concordance rate in dizygonic twins, the rarity of conjugal multiple sclerosis (27) the lack of a birth order effect (28) and the identification of resistant groups living in high prevalence zones, all argue against a purely transmissible factor (29). A simple view would be that, of the candidate genes which have been examined as markers of susceptibility, only the DR15 class 2 major histocompatibility complex (MHC) allele association in northern Europeans holds up to critical analysis. The specifically different associations with DR4 in Japanese (30) and Jordanians (31) have never been confirmed although multiple sclerosis does appear be DR4 associated in Sardinians (8). There is no evidence that any genetic marker, acting alone or in combination, protects individuals from development of the disease. Reports that the severity of multiple sclerosis correlates with the presence of specific susceptibility alleles, or that the primary progressive form of the disease is associated with a specifically different set of susceptibility markers (32-33), remain unconfirmed.

The role of the HLA system in conferring susceptibility to MS has been demonstrated by population association studies, but these do not resolve the question of which class 2 region allele makes the primary contribution. The association also is varied in different races. For these reasons we studied the role of HLA system in 79 Caucasoid Iranian patients with definite MS (15).

Seventy- four patients were classified as having relapsing-remitting (RR) MS, with distinct (11) attacks and stable phases in between. This group consisted of 48 females and 26 males with an age range of 18 to 50 years (mean 31 ± 7.3), disease duration of 4.2 ± 3.3 years and an EDSS of 1.9 ± 1.1.

Five patients were classified as primary progressive (PP) MS (11) having had a steady progressive course. This group consisted of four females and one male with age range of 37 to 61 years (mean 48.4 ± 9.9), disease duration of 8.6 ± 6.8 and EDSS of 4.3 ± 2.3.

From 51 antigens tested and compared with 100 controls (13A, 18B, 5C, 12 DR, 3 DQ), it was found that the distribution of HLA antigens show a preponderance for HLA-DR15 and to a lesser degree for HLA- DR2 and HLA- A24 in MS patients. On the other hand, HLA-B15, B40, DR4, DR52 and DQ3 are significantly under-represented in MS.

The same was true for HLA-A28, B5, B14, and CW2 but to a lesser degree. Segregating patients according to age of onset, revealed no significant differences in the distribution of HLA antigens. Thus the 65 Ms patients with age at onset before 35 years had HLA- DR15, DR2 and A24 frequencies of 36.5, 43 and 31.08% respectively. Corresponding frequencies for the 14 patients with onset after 35 years were 37, 43 and 29.9% respectively. When HLA types were analysed for RR and PP subgroups, no significant differences were noted.

No MS patients had severe disease with a Kutzke score of five or more within 5 years of their first symptoms.

Clinical symptoms and physical findings

Although the clinical syndrome of MS is classically described as a relapsing- remitting disorder that affects multiple white matter tracts within the CNS, with usual onset in young adults, the disorder displays marked clinical heterogeneity. This variability includes age of onset, mode of initial manifestation, frequency, severity and sequealae of relapses, extent of progression and certain specific clinical and neuro-immunological features. For these reasons we decided to study the clinical course and pattern of presentation of the disease in an Iranian MS population. The study period was form July 1996 to July 2001, during which 200 cases ware evaluated (21).

The RR from was the most common clinical presentation, with 179 case(88%) followed by PP with 14 cases (7%)

and SP with 10 cases (5%). the mean age of onset for the entire group of 200 patients was 27 ± 7.4 years, with disease duration of 5.5 ± 4.7 years and an EDSS score of 2.1 ± 1.4.

The PP group had a higher age at onset (37.1 ± 8.8 years) with female preponderance (10 out of 14). In 12 cases, spinal signs were first presented in the form of paraparesis with or without sphincter or sensory disturbance. In two cases, the presenting symptom was of cerebellar nature followed by spinal signs.

Women represented 72% of cases giving a gender ratio of 2.5:1 female: male. While the yearly number of attacks in the RR groups was 0.4, SP patients had an average of 1.2 attacks per year, for their average of 10 ± 6.1 years before entering this phase. Almost all of the SP cases had spinal or cerebellar signs at the onset of the disease.

The most common presenting symptoms were weakness in one or more limbs (33%) followed by sensory impairment (24%), sphincter disturbance (20%), Visual impairment (20%), Ataxia (15%), vertigo (10%), Diplopia (5%), Bell's palsy (3%) and seizure (3%). Twenty- seven percent of cases had more than one symptom. Eight patients had optico- spinal presentation of RR type with simultaneous or consecutive visual and spinal impairments of motor and/or sensory nature, with mean disease duration of three years and an EDSS score of 1.3. Ninety per cent of patients were of middle-income class, 65% had a high school diploma and 30% were educated at university level. Ten patients (5%) had a positive family history, each one with one first- degree affected relative. While 28(14%) benign cases were recorded (34) with an EDSS score of 3 or less after 10 years, 24 patients had disease duration of five years or more with an EDSS score of 2 or less.

Discussion

HLA typing, natural course and clinical findings of 79 and 200 definite MS cases in Iran were respectively reviewed (15, 21).

Results, drawn from our 79 Iranian MS patients reveal an association between MS and HLA types- A24, DR2, and DR15, each with a relative risk of 1.9 times that of controls. This genetically determined increased risk is best explained by assuming the existence of an MS susceptibility gene which has been identified in linkage studies with HLA-DR15 and DR2 loci on chromosome 6. This association of DR2 and DR15 HLA types with MS in Iranian patients is in line with studies done in other parts of the world (34-37). In the analysis of HLA class I, we found a positive association with A24 but no association with B locus alleles. The association of HLA-A locus in Iranian MS differs from previous studies in other parts of the world (35, 38-39) as well as Asian countries (40-41). In fact Indian investigators identified an association between HLA B12 and MS (40).

Of interest is the under-representation of the following alleles in Iranian MS patients: HLA-A28, B5, B14, CW2 ($P<0.05$) and HLA-B15, B40, DR-4, DR-52, and DQ3($P<0.005$).

Whether these alleles have any protective role against MS in this geographic region to be determined.

Iran is traditionally though to be situated in a low risk zone for MS (21). Here MS presents with involvement of multiple sites in the central nervous system (CNS), including the cerebrum, cerebellum or brainstem, which is similar to its behavior in the Caucasian population. Having RRMS as the most frequent type of presentation, followed by the PP form with a higher age of onset and worse prognosis, and female preponderance in both types, are in agreement with European and Latin American Studies (42-45). The most common presenting symptoms of pyramidal and sensory involvement in the present cases have also been reported from neighboring Middle East countries and Europe (12, 42). Compared with the RR group, SP had more annual attacks with pyramidal or cerebellar dysfunction as their presenting signs. The presence of 28 patients with an EDSS score $\leq$ 3 after 10 years and 24 with an EDSS score ≤ 2 after five years indicates a benign course for MS in this country. Optico-Spinal MS, which is a common presentation of the disease in Asian countries and is called Asian type (46), is not a prominent feature here, probably due to different HLA typing.

It is believed that we are facing a rising incidence of MS similar to other countries (12, 45, 47). This may be explained by increased survival, improved laboratory and radiological diagnoses. However, a decreased number with SP form, which is a natural endpoint of the RR type, may indicate that more new cases are being diagnosed, and other possibilities should be looked for (21).

References

1. Bartlett PF, Kilpatrick TJ. Neuroimmunology of demyelinating disease. Curr Opin Neurol Neurosurg 1991; 4:181-85.

2. Rolak L.A. Demyelinating disease. In Rolak LA ed. Neurology secrets. Philadelphia, PA: Hanley & Belfus, 1993: 185-92.

3. Sadovinck AD, Ebers GC, Dyment DA. Evidence for genetic basis of multiple sclerosis. Lancet 1996; 347: 1728-30.

4. Hartung HP. Immune- mediated dymelination. Ann Neurol. 1993; 33:563-67.

5. Acheson ED. Epidemiology of multiple sclerosis. Br Med Bull. 1997;33:9-14.

6. Oger J, Amason BGW. HLA patterns in multiple sclerosis in: Bauer H (ed). Progress sclerosis research. Springer-Verlag: Berling. 1980: 460-464.

7. Kurdi A, Ayesh I, Abdallat A. Different B Lymphocyte aloantigens associated with multiple sclerosis in Arabs and Northern Europeans. Lancet i; 1977: 1123-1125.

8. Marrosu MG, Muntoni F, Murru MR. HLA-DQBI genotype in Sardinian multiple sclerosis; evidence for a key role of DQBI. 0201 and DQBI. 0302 alleles. Neurology 1992; 42: 883-885.

9. Marrosu MG, Murru MR, Costa G. DRBI-DQAI- DQBI Loci and multiple sclerosis predisposition in the Sardinian population . Hum Mol Genet. 1998; 7-8: 1235-1237.

10. Ebers GC, Dyment DA, Genetics of multiple sclerosis. Semin Neurol. 1998; 18: 295-299.

11. Poser CM, Paty DW, Scheinberg L. New diagnostic criteria for multiple sclerosis guidelines for research protocols. Am Neurol 1983: 13: 227-31.

12. Daif AK, Al-Rajeh S, Awada A. Pattern of presentation of multiple sclerosis in Saudi Arabia; analysis based on clinical and paraclinical features. Eur Neurol 1998; 39:182-86.

13. Acheson ED. Epidemiology of multiple sclerosis, Br Med Bull 1997; 33: 9-14.

14. Oger J, Arnason BW. HLA patterns in multiple sclerosis. In Bauer H ed. Progress in multiple sclerosis research. Berlin: Springer- Verlag, 1980:460-64.

15. Kalanie H, Kamgooyan M, Sadeghian H. Histo-compatibility antigen association with multiple sclerosis in Iran. Mult Scler 2000; 6:317-19.

16. AI Rajeh S, Bademosi O, Ismail H. A community survey neurological disorders in Saudi Arabia: the Thughbah study. Neuroepidemiology 1993; 12: 164-78.

17. Yaqub BA, Daif AK. Multiple sclerosis in Saudi Arabia. Neurology 1988; 38 : 621-23.

18. al-Din AS, Khogali M, Poser CM. Epidemiology of multiple sclerosis in Arabs in Kuwait: a comparative study between Kuwait and Palestinians. J Neurol Sci 1990; 100: 137-41.

19. al-Din AS, el-Khateeb M, Kurdi A. Multiple sclerosis in Arabs in Jordan. J Neurol Sci 1995; 131: 144-49.

20. al-Din AS. Multiple sclerosis in Kuwait: Clinical and epidemiology study. J Neurol Neurosurg Psychiatry. 1986; 49: 928-31.

21. Kalanie H, Gharagozli K, Kalanie AR. Multiple sclerosis: Report on 200 case from Iran. Mult Scler 2003; 39: 36-38.

22. Weinshenker BG. Epidemiology of multiple sclerosis. Neurol Clin 1996; 14: 291-308.

23. Kurtzke JF. MS from an epidemiological view point. Lancaster: MTP Press LTD. 1977: 83-83.

24. Ebers GC, Bulman DE, Sadovinck AD. A population based study of multiple sclerosis in twins. New Eng J Med 1986: 315: 1638-1642.

25. Sadovinck AD, Armstrong H, Rice GP. A population based study of multiple sclerosis in twins: update. Ann Neurol 1992: 33: 281-285.

26. Mumford CJ, Wood NW, Kellar-wood HE. The British Isles survey of multiple sclerosis in twins. Neurology 1994:44:11-15.

27. Schapra K, Poskanzer DC, Miller H. Familial and conjugal multiple sclerosis. Brain 1963; 86: 315-332.

28. Ebers GC, Cripps J, Rudo A. Birth order and multiple sclerosis. Acta Neurol scand 982: 66: 342-346.

29. Ebers GC, Sadovinck AD. The role of genetic factors in multiple sclerosis susceptibility: a critical review. J Neuroimmune 1994: 54: 1-17.

30. Batchlor JR, Compston DAS, McDonaldn WI. The significance of the association between HLA and multiple sclerosis. Br Med Bull 1978: 34: 279-284.

31. Kurdi A, Ayesh I, Abdallat A. Different B lymphocyte alloantigen associated with multiple sclerosis in Arabs and North Europeans. Lancet 1977; 1123-1125 multiple sclerosis: evidence for a key role of DQBI. 0302 alleles. Neurology 1992: 883-886.

32. Olerup O. Hillert J, Fredrikson S. Primarily chronic progressive and relapsing/remitting multiple sclerosis: two immunogeneticall distinct disease entities. Proc Natl Acad USA 1989: 86: 7113-7117.

33. Thompson AJ, Hutchinson M, Brazil J. A clinical and laboratory study of benign MS. QJ Med 1986; 58: 69-80.

34. Francis DA and the British & Dutch multiple sclerosis azathioprine trial group. Histocompatibility antigens in multiple sclerosis patients participating in a multicentre

trial of azathioprine. J Neurol Neurosurg Psych. 1998; 51: 412-415.

35. Alvarado-dc la Barrera C, Zuntiga-Ramos J, Ruiz-Morales JA, et al. HLA class II genotypes in Mexican Mestizos with familial and nonfamilial multiple sclerosis. Neurology 2000; 55: 1897-900.

36. Pina MA, Ara JR, Lasierra P. Study of HLA as a predisposing factor and its possible influence on the outcome of multiple sclerosis in the sanitary district of Calatayud, northern Spain. Neuroepidemiology 1999; 18: 203-209.

37. Odinak MM, Bisaga GN, Kalinina NM. Multiple sclerosis in northern-west region of Russia: results of HLA-typing, Zh Nevrol Psikhiatr Im S S Korsakova 2000; 100: 40-4.

38. Shiralieva RK, Guseinova KA. Characteristic of histocompatibility antigens distribution in patients with multiple sclerosis. Klin Med Mosk 1998; 76: 19-20.

39. Wadia NH, Trikannad VS, Krishnaswamy PR. Association of HLA- B12 with multiple sclerosis in India. Tissue Antigens 1980; 15: 90-93.

40. Wadia NH, Trikannad VS, Krishnaswamy Pr. HLA antigens multiple sclerosis amonges Indians. J. Neurol Neurosurg Psychiatry 1981; 44: 849-851.

41. Ono T, Zambenedetti MR, Yamasaki K. Molecular analysis of HLA class I (HLA-A and B) HLA class II (HLA-DRBI) genes in Japanese patients with multiple sclerosis (Western type and Asian type). Tissue Antigens 1998; 52:539-552.

42. Moreira MA, Felipe E, Mendes MF. Multiple sclerosis: descriptive study of its clinical forms in 302 cases. Arq Neuropsiquiatr 2000; 58: 460-66.

43. Berne- Bernady P, Preux PM, Preux C. Case study of 199 patients with multiple sclerosis: the use of EDMUS program. Rev Neurol 2000; 156: 41-46.

44. Arruda WO, Scola RH, Teive HA. Multiple Sclerosis: report on 200 cases From Curitiba, Southern Brazil comparison with other Brazilian series. Arq Neuropsiquiatr 2001; 56: 165-70.

45. McDonnell GV, Hawkins SA. An epidemiologic study of multiple sclerosis in Northern Ireland. Neurology 1998; 50: 423-2.

46. Kira J, Kanai T, Nishimura Y. Western versus Asian types of multiple sclerosis: immunogenetically and clinically distinct disorders. Ann Neurol 1996; 40: 569-74.

47. Syal P, Prabhakar S, Thussu A. Clinical profile of multiple sclerosis in north-west India. Neurol India 1999;47:12-17.